BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3042583)

  • 1. Prognostic factors in decision-making in the clinical management of Hodgkin's disease.
    Hagemeister FB
    Hematol Oncol; 1988; 6(3):257-69. PubMed ID: 3042583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
    Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT
    J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
    Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
    J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
    Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
    Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up.
    Olver IN; Wolf MM; Cruickshank D; Worotniuk V; Ding JC; Cooper IA; Matthews JP
    Cancer; 1988 Jul; 62(2):233-9. PubMed ID: 3383124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
    Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
    J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases treated with a MOPP-modified protocol.
    Silingardi V; Federico M; Frassoldati A; Barbieri F; Palomba G; Mauri C
    Acta Haematol; 1989; 82(4):179-86. PubMed ID: 2511719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year nodular sclerosis Hodgkin's disease and second malignancies.
    Zulian GB; Mirimanoff RO
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):659-65. PubMed ID: 2714343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease.
    Levis A; Vitolo U; Ciocca Vasino MA; Cametti G; Urgesi A; Bertini M; Canta M; Monetti U; Bosio C; Jayme A
    Cancer; 1987 Oct; 60(8):1713-9. PubMed ID: 3651998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research and Treatment of Cancer.
    Carde P; Hayat M; Cosset JM; Somers R; Burgers JM; Sizoo W; Meerwaldt JH; Hagenbeek A; Monconduit M; van der Schueren E
    NCI Monogr; 1988; (6):303-10. PubMed ID: 3352775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease.
    Huguley CM; Durant JR; Moores RR; Chan YK; Dorfman RF; Johnson L
    Cancer; 1975 Oct; 36(4):1227-40. PubMed ID: 1175125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
    Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM
    Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone.
    Mauch P; Goffman T; Rosenthal DS; Canellos GP; Come SE; Hellman S
    J Clin Oncol; 1985 Sep; 3(9):1166-73. PubMed ID: 3839844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality treatment of Hodgkin's disease confined to lymph nodes. Results eight years later.
    Wiernik PH; Gustafson J; Schimpff SC; Diggs C
    Am J Med; 1979 Aug; 67(2):183-98. PubMed ID: 380335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
    Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
    Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
    Fuller LM; Hagemeister FB
    Recent Results Cancer Res; 1989; 117():197-204. PubMed ID: 2602645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.